Top 13 Journals in Dermatological Science Ranked by Web of Science (WOS) – 2024

List of Top Most Dermatological Science Journals Ranked by WoS

Source

1. https://mjl.clarivate.com/
2. https://doi.org/10.13140/RG.2.2.22948.45444

In academia, publishing articles showcases expertise and credibility. Journals with high impact factors signal significance in the field. Understanding how to gauge a journal’s impact can enhance your publication strategy. Impact factor, a key metric, reflects a journal’s influence over time. Calculating it involves dividing the number of citations by the total articles published. Assessing personal impact also matters, considering citations to your own work. This article explores the significance, methodology, and implications of impact factors, empowering academics and professionals to navigate the publishing landscape strategically and enhance their scholarly footprint.

What is Impact factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of citations of articles published in the last two years in a given journal, as indexed by Clarivate’s Web of Science.

As a journal-level metric, it is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are given the status of being more important, or carry more prestige in their respective fields, than those with lower values.

While frequently used by universities and funding bodies to decide on promotion and research proposals, it has been criticised for distorting good scientific practices [1-3].

Read More: Top Open Peer-Reviewed Journals in Medical Science

Why is the impact factor important?

Impact factor, an index based on the frequency with which a journal’s articles are cited in scientific publications, is a putative marker of journal quality [4]. A journal’s impact factor holds immense sway over funding, submissions, and the reputation of publishers and academics. Upholding publication quality not only boosts citation rates but also enhances a journal’s ranking. High impact factor journals signal meticulous management and prestige, fostering a virtuous cycle of scholarly engagement and recognition.

How to calculate the journal impact factor?

Journal Impact Factor (JIF) is calculated by Clarivate Analytics as the average of the sum of the citations received in a given year to a journal’s previous two years of publications (linked to the journal, but not necessarily to specific publications) divided by the sum of “citable” publications in the previous two years [5].

The calculation is based on a two-year period and involves dividing the number of times articles were cited by the number of articles that are citable.

Calculation of 2010 IF of a journal:

A = the number of times articles published in 2008 and 2009 were cited by indexed journals during 2010.
B = the total number of “citable items” published in 2008 and 2009.

A/B = 2010 impact factor

The Impact Factor is reported in Journal Citation Reports (JCR)
CiteScore, which is similar to the IF but is based on a 4-year period.

Impact Factor Controversy

The impact factor (IF), widely used in academia, has sparked debate due to its limitations. It quantifies a journal’s influence based on citations received by its articles within a specific time frame (usually two years). However, critics argue that it oversimplifies research quality and favors certain fields [6]. Indeed, the fact that it is simple to understand – it is roughly the average number of citations that primary research papers published in two consecutive years gather in the following year – makes it all too easy to point out its shortcomings: the metric also includes citations to non-primary content (such as reviews and news articles); for many fields, citations accumulate slowly and thus the two-year time window seems too short; and the average number of citations per paper can be skewed by a few highly cited ones, of which high-impact journals have a big share [7]. Furthermore, a recent study found that papers published in predatory journals, which often lack rigorous peer review, have little scientific impact. Around 60% of these papers hadn’t attracted any citations at all, and less than 3% received more than 10 citations [8]. As we rethink science publishing, there’s a growing need for a broader, more-transparent suite of metrics to judge journals beyond the traditional impact factor [9]. Researchers and institutions should consider these complexities when evaluating scholarly work and avoid relying solely on impact factors for assessing journal quality.

Recent Biggest Discoveries and advances in Dermatological Science (2024)

1. Gene Mutation Linked to Psoriasis and Psoriatic Arthritis:

1. • Scientists from The Australian National University (ANU) have identified a gene mutation responsible for causing psoriasis, a chronic inflammatory skin disease characterized by red, scaly, and itchy patches. If two copies of this mutated gene (known as IKBKB) are present, patients with psoriasis may go on to develop psoriatic arthritis, leading to joint pain, stiffness, and swelling. This discovery sheds light on the progression from a skin-only disease to a skin and joint condition [10].

2. Dupilumab for Chronic Hand Eczema:

1. • Dupilumab, a monoclonal antibody, has shown promise in treating recalcitrant chronic hand eczema. This condition can be challenging to manage, but this medication offers hope for patients with persistent symptoms [11].

3. Topical Roflumilast for Seborrheic Dermatitis:

1. • Topical roflumilast has been investigated as a potential treatment for seborrheic dermatitis [12].

4. Investigational Nemolizumab for Prurigo Nodularis:

1. • Researchers are exploring the use of nemolizumab for prurigo nodularis, a condition characterized by intensely itchy nodules on the skin [13].

5. Second Primary Cancers in Pediatric Melanoma Survivors:

1. • A study investigated second primary cancers in pediatric and young adult survivors of cutaneous melanoma. Understanding these risks is crucial for long-term management [14].

6. Skin Grafting for Dermatologists: Past, Present, and Future:

1. • A comprehensive review article discusses the history, current practices, and future prospects of skin grafting in dermatology [15].

References

1. Waltman L, Traag VA (1 March 2021). “Use of the journal impact factor for assessing individual articles: Statistically flawed or not?”. F1000Research. 9: 366. doi:10.12688/f1000research.23418.2
2. Curry S (February 2018). “Let’s move beyond the rhetoric: it’s time to change how we judge research”. Nature. 554 (7691): 147. Bibcode:2018Natur.554..147C. doi:10.1038/d41586-018-01642-w
3. Hutchins, BI; Yuan, X; Anderson, JM; Santangelo, GM (September 2016). “Relative Citation Ratio (RCR): A New Metric That Uses Citation Rates to Measure Influence at the Article Level”. PLOS Biology. 14 (9): e1002541. doi:10.1371/journal.pbio.1002541
4. Saha S, Saint S, Christakis DA. Impact factor: a valid measure of journal quality? J Med Libr Assoc. 2003 Jan;91(1):42-6. PMID: 12572533; PMCID: PMC141186.
5. Measuring a journal’s impact. https://www.elsevier.com/en-in/researcher/author/tools-and-resources/measuring-a-journals-impact
6. The impact-factors debate: the ISI’s uses and limits – Nature. https://www.nature.com/articles/415731a.pdf.
7. The diversifying nature of impact – Springer Nature. https://media.springernature.com/full/springer-cms/rest/v1/content/16138586/data/v2.
8. Chawla, Dalmeet Singh. “Predatory-journal papers have little scientific impact.” Nature(2020). https://www.nature.com/articles/d41586-020-00031-6
9. Wouters, P., Sugimoto, C. R., Larivière, V., McVeigh, M. E., Pulverer, B., de Rijcke, S., & Waltman, L. (2019). Rethinking impact factors: better ways to judge a journal. Nature, 569(7758), 621-623. https://www.nature.com/articles/d41586-019-01643-3
10. Cardinez, C., Hao, Y., Kwong, K. et al.IKK2 controls the inflammatory potential of tissue-resident regulatory T cells in a murine gain of function model. Nat Commun15, 2345 (2024). https://www.nature.com/articles/s41467-024-45870-3
11. Angelique N Voorberg, Esmé Kamphuis, Wietske A Christoffers, Marie L A Schuttelaar, Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study, British Journal of Dermatology, Volume 189, Issue 4, October 2023, Pages 400–409, https://academic.oup.com/bjd/article/189/4/400/7160661
12. Zirwas MJ, Draelos ZD, DuBois J, et al. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial. JAMA Dermatol.2023;159(6):613–620. https://jamanetwork.com/journals/jamadermatology/fullarticle/2804569
13. Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., … & Ständer, S. (2023). Phase 3 trial of nemolizumab in patients with prurigo nodularis. New England Journal of Medicine, 389(17), 1579-1589. https://www.nejm.org/doi/10.1056/NEJMoa2301333
14. Luu, Y., Han, J., Agarwal, A., Elkady, N., Jaroonwanichkul, S., Gulati, N., & Gittler, J. (2024). Risk for second primary cancers among pediatric and young adult melanoma survivors. Pediatric Dermatology, 41(1), 12-15. https://onlinelibrary.wiley.com/doi/10.1111/pde.15421
15. Maskan Bermudez, N., Sa, B.C., Hargis, A. et al.Skin Grafting for Dermatologists: Past, Present, and Future. Curr Derm Rep(2024). https://link.springer.com/article/10.1007/s13671-024-00427-x

Last update: 04-May-2024